B
one morphogenetic proteins (BMPs), a class of proteins that can induce bone and cartilage tissue formation, were first identified by Urist 1 in 1965. In addition to their functions in the induction of bone and cartilage tissue formation, BMPs have biological activities in multiple tissues and organs. Therefore, BMPs are also termed body morphogenetic proteins by Reddi. 2 In humans, the BMP family includes a total of 19 types of proteins. Bone morphogenetic protein-2 and BMP-11 induce bone tissue calcification and increase the osteocalcin level in the cells expressing C1C12. 2 Bone morphogenetic protein-12, BMP-13, and BMP-14 are regarded as cartilage-derived morphogenetic proteins (CDMPs), which are characterized by chondrogenic activity. Bone morphogenetic protein-15, BMP-16, BMP-17, and BMP-18 exhibit no obvious effects on the cartilage and bone induction. 2 However, many problems are present in the isolation, purification, and mass production of BMPs.
Since BMP was identified, there have been many attempts to isolate and purify the BMPs from rabbit, bovine, and human bones. 2 However, the methodology available for isolation and purification of BMPs is an extremely complex purification procedure with a low production rate (1-3 vg/kg cortical bone) 3 and a risk of rejection reactions. 2 Therefore, different methods were introduced to increase the production rate by preparing recombinant BMPs (rBMPs) with gene recombination techniques. 2 Two pathways have been mainly used for the production of rBMPs: the mammalian cell pathway and the bacterial pathway (mainly Escherichia coli). 4 Recombinant human BMPs (rhBMPs) derived from eukaryotic mammalian cells show biological activity; however, the production remains at an extremely low level. 4 Recombinant human BMPs have the advantages of rapid isolation, mass production, and economic recovery. 4 However, the proteins locate in the insoluble infusion body, 4 leading to extremely time-consuming isolation and purification procedures, which require a late-phase renaturation to improve the biological activity of the product. 4 The role of BMP-2 in the induction of bone and cartilage formation has been widely recognized. 2, 4 Recombinant human BMP-2 was first identified in Chinese hamster ovary (CHO) cells in 1990 by Wang et al. 5 Currently, the clinically available rBMPs (including rhBMPs) are all derived from mammalian cell cultures. 4 This also includes the US Food and Drug Administration-authenticated collagen carrier products containing rhBMP-2 and rhBMP-7 (INFUSE Bone Graft; Medtronic Spinal and Biologics, Memphis, Tennessee). 2, 4 Recombinant human BMP-2 has been proven to actively promote bone fusion in human as well as nonhuman species with a better efficacy than that of autogenous iliac bone, 6, 7 which results in its wide application in spinal fusion, fracture healing, and dental tissue engineering. 8 It has been reported that adequate production of rhBMP-2 with a good biological activity was yielded from E coli-derived rhBMP-2 (ErhBMP-2) through modification of the preparation method. 4 However, most of the biological activity tests are established on the basis of in vitro experiments to test the alkaline phosphatase activity in mouse C2C12, MC3T3-E1, and CH310T1/2 cells and human stem cells. 4, 9 The activity of ErhBMP-2 remains controversial in in vitro animal model experiments. Comparison of rhBMP-2 and ErhBMP-2 efficacy to promote bone healing in a standardized experimental bonehealing model in rat mandibles revealed that higher doses of ErhBMP-2 were required to achieve similar efficacy of bone healing to that of rhBMP-2 expressed in mammalian cell lines. 10 Similar results were observed in mouse models, and the ability of ErhBMP-2 to induce bone formation was found to be one-fifth to onetenth of rhBMP-2. 6 It has been recently demonstrated in animal experiments that the biological action of ErhBMP-2 is similar to that of rhBMP derived from CHO cells. However, most of these experiments were conducted in rodents 3 and a few in rabbit models 11 and large-animal models like canines. 12 In addition, there have been only 2 studies that involved animal models of spinal fusion, which reported the efficacy of ErhBMP-2 in posterolateral lumbar fusion in a rabbit model. 11, 12 Therefore, the currently available evidence is insufficient to support the clinical application of ErhBMP-2, and there are no reports on the use of ErhBMP-2 in cervical interbody fusion in large-animal models. The goat cervical spine has good comparability with the human spine, which has encouraged the use of the goat cervical spine as a model for cervical spine research. In addition, the biomechanical environment of the goat spine is similar to that of humans. 13 Therefore, the goat C3-C4 segment seemed to be the most reliable model for the corresponding human motion segment.
The CHO cell-derived rhBMP-2 has been reported to be safe, with no side effects.
14 However, it has been demonstrated that the rhBMP-2 derived from CHO cells might induce the early subsidence of infusion cages.
14 Although ErhBMP-2 has been reported to cause bone resorption and destruction, 12 the adverse effects remain unclear given that it has not been applied in clinical practices. The efficacy of ErhBMP-2 has been evaluated in posterolateral lumbar fusion 12 ; however, the subsidence of infusion cages could not be assessed. The commonly used absorbable collagen sponge (ACS) derived from the calf tendon exhibited a bioabsorbable activity along with a high release and synergistic function on BMPs. 15 However, the ACS has been reported to lack the space-maintaining ability and mechanical support ability. 12, 15 Therefore, the ACS, as a carrier, cannot be used to evaluate the effect of ErhBMP-2 on interbody space height postoperatively. Beta-tricalcium phosphate (ß-TCP), a new absorbable biological ceramic material, has been successfully used in orthopedic and dental surgeries. 16 It has been reported that ErhBMP-2 combined with ß-TCP was able to induce new bone formation and provide an implant stent, which has been validated in animal models. 12 However, all ß-TCPs used in these experiments were previously ErhBMP-2-adsorbed ß-TCP granules. In the current study, the authors used a novel ErhBMP-2/ACScoated enhanced cervical interbody fusion cage containing ß-TCP to adequately maintain the interbody space height and induce bone formation to assess postoperative changes in the interbody space height. It consisted of a dense peripheral part with a high mechanical performance and functionality in a support and stent role and a multipore central part with a good micropore structure and high biological performance. 16 
Materials and Methods

Animals and Grouping
A total of 36 healthy 2-year-old male adult goats, with individual body weight differences within 10%, were randomly grouped into groups A (autogenous iliac bone grafting; n=12), B (cervical interbody fusion cage containing ß-TCP [Shanghai Bio-lu Biomaterials Co Ltd, Shanghai, China]; n=12), and C (cervical interbody fusion cage [ACS carrier] containing ß-TCP+2.5 mg ErhBMP-2 [Shanghai Rebone Biomaterials Co Ltd, Shanghai, China]; n=12). Postoperatively, each group was further assigned into 2 subgroups: 3-month postoperative (n=6)and 6-month postoperative (n=6) ( Table 1) .
Surgical Technique and Specimen Processing
All surgeries were performed with an enhanced cervical interbody fusion cage containing ß-TCP. The fusion cage was a box-like shape, with its cross-section being an approximate trapezoid. The periphery was dense and the center was multipore, with a 10-mm width, 8-mm anteroposterior diameter, and 4.5-mm height (Figure 1) .
General anesthesia was routinely administered to all animals. Goats in group A were placed in the right lateral position. After the left posterior superior iliac spine was identified, the tricortical bone was collected with an osteotome, and the iliac bones were mended to masses measuring 10×8×4.5 mm for the subsequent experiment. Goats in all 3 groups were fixed on special fixed brackets in the supine position after collection of the iliac bones. The hair on the neck was shaved, and the skin was disinfected. The skin on the right side was vertically incised anterior to the neck, followed by blunt dissociation down to the prevertebral fascia and anterior longitudinal ligament. After the C3-C4 intervertebral space was identified using C-arm radiography, the intervertebral disk tissues were removed and the lamina terminalis was appropriately treated. The autogenous tricortical iliac crest bone graft or cervical interbody fusion cage containing ß-TCP (mixed with ErhBMP-2) was implanted, and the intervertebral space was fixed with steel plates containing locks. The bleeding was completely stopped, and the surgical field was flushed with physiological saline. Finally, continuous suturing of the deep fascia and skin incisions was performed.
All goats were humanely killed 3 or 6 months postoperatively. The intervertebral space and the 2 vertically neighboring vertebral bodies at the surgical segments were completely dissociated, followed by removal of the titanium plate and screws. The specimens were marked clearly, fixed in 10% formaldehyde for 7 days, dehydrated with a graded series of methanol, and embedded in methylmethacrylate.
Data Collection and Fusion Assessment
Evaluation of Imaging Data. Anteroposterior lateral radiography of the cervical vertebra was performed immediately, 3 months, and 6 months postoperatively. Computed tomography (CT) scanning of the cervical vertebrae was performed 3 and 6 months postoperatively (Figure 2) . The anterior height of the intervertebral space (aDSH), the height of the lamina terminalis midpoint (mDSH), and the posterior height of the intervertebral space (pDSH) were measured on lateral radiographs of the cervical vertebrae. The mean height was defined as the mean intervertebral height 17 and was calculated by the formula (aDSH+mDSH+pDSH)/3. Sagittal reconstruction of the surgical segments on CT images was performed, and the fusion was scored in 3 divided regions: the upper lamina terminalis on the intervertebral space, the loose part in the middle of the fusion cage (autogenous iliac bone was considered as the default, with a score of 2), and the lower lamina terminalis on the intervertebral space. The maximum score of the reconstructed plane was recorded. The criteria for CT scoring included 17 : 0, no new bone formation; 1, new bone formation with no synostosis between the vertebral body and the grafts; and 2, no synostosis between the vertebral body and the grafts.
Evaluation of Histological Data. Methylmethacrylate-embedded specimens were cut into undecalcified hard tissue sections using a microtome. Three slices were sampled from the specimens of the cervical vertebrae in each goat, which was close to the midline of the sagittal plane ( Figure  3 ). This was followed by van Gieson picric acid fuchsin staining. 18 Intervertebral fusion was observed under an inverted fluorescence microscope, and the images were photographed and saved in TIFF format (Figure 3) . The images were quantitatively evaluated using Image-Pro Plus version 5.0.0.39 software (Media Cybernetics, Warrendale, Pennsylvania). The hard tissue sections were observed under an inverted fluorescence microscope, and the area of each tissue structure was calculated in the multipore part at the 2-dimensional field of view. The new bone area (NBA) and residual material area (RMA), which reflected the volume of the new bones and residual materials in the multipore part, were evaluated. The aforementioned data were obtained by estimations performed on the microscopic images from the multipore region of the hard tissue slices using Image-Pro Plus version 5.0.0.39 software. Furthermore, the depth of tissue penetration (DTP) was evaluated, which indicated the depth of bone tissue penetration into the multipore part. The DTP was calculated under the field of view of the slices using the following formula: DTP=penetration depth of bone tissues at the midpoint of the 4 sides/circumference of the multipore part. The mean penetration depth ratio was calculated using the following formula: mean penetration depth ratio=DTP/height of the fusion cage (4.5 mm). The material degradation rate (MDR) was also calculat- n Feature Article ed using the following formula: MDR=(1-RMA/area of the multipore part)×100%. The integration of the new bones and the dense part of the fusion cage was quantitatively evaluated by calculating the ratio of the length of the integration of new bones and the dense part of the fusion cage to the circumference of the dense part. All experimental data were independently recorded by 2 observers (H.W., F.Z.). If there was a large difference between the 2 observers, the data were recaptured and reevaluated to ensure the authenticity and validity of the data.
Statistical Analysis
Statistical analyses were performed using SPSS version 16.0 statistical software (SPSS Inc, Chicago, Illinois). The Kruskal-Wallis test was used to compare the mean height of the intervertebral space on the cervical vertebrae lateral radiograph immediately, 3 months, and 6 months postoperatively. Intervertebral fusion scores on plain CT scans and 2-dimensional sagittal reconstruction, NBA, and MRA were compared between groups using 1-way analysis of variance 3 and 6 months postoperatively. Twoindependent-samples t test was used to compare NBA, MRA, mean penetration depth, MDR, and the integration ratio of new bones and the dense part of the fusion cage between groups B and C. A P value less than .05 was considered to demonstrate a statistically significant difference.
results
Of the 36 goats, 2 died from intervertebral space infection postoperatively and 1 died from pulmonary infection. The animals were supplemented according to the designed experimental protocol. Redness and swelling of the iliac bone incision occurred in 1 goat, which was cleared following antibiotic therapy. The other goats had a good postoperative general condition with no obvious surgeryassociated complications observed. Some fusion cages were broken and ruptured postoperatively, followed by the loss of intervertebral space height. Table 2 presents mean height of the intervertebral space in the cervical vertebra lateral radiographs. There was no significant difference in the intervertebral height among groups A, B, and C at 3 months postoperatively (x 2 =1.537; P=.464). This finding demonstrated that the cervical interbody fusion cage containing ß-TCP, the cervical interbody fusion cage containing ß-TCP+ErhBMP-2, and autogenous iliac bone grafting had a similar ability to maintain cervical intervertebral height at 3 months postoperatively. Furthermore, there was no significant difference in intervertebral height between groups A, B, and C at 6 months postoperatively (P=.043), which indicated that the ability of the cervical interbody fusion cage containing ß-TCP to maintain the cervical intervertebral height was significantly different from that of the autogenous iliac bone grafting at 6 months postoperatively. Stepwise multiple comparisons, following the rank transformation with the least significant difference method, revealed significant differences between group A and groups B and C (P=.012 and .049, respectively). No significant difference was observed between groups B and C (P=.492), which indicated that the cervical interbody fusion cage containing ß-TCP, with or without BMP, had a higher ability to maintain the intervertebral height at 6 months postoperatively compared with that of autogenous iliac bone grafting. Furthermore, the addition of BMP had no significant effect on the ability to maintain intervertebral height. The intervertebral heights in groups A, B, and C were not significantly different at 3 months postoperatively as compared with those at 6 months postoperatively (P=.507, .701, and .61, respectively).
Analysis of Imaging Data
There was no significant difference in fusion scores between groups A, B, and C at 3 months postoperatively (F=1.622; P=.23). This indicated that the cervical interbody fusion cage containing ß-TCP, the cervical interbody fusion cage containing ß-TCP+BMP, and autogenous iliac bone grafting achieved similar efficacy of intervertebral fusion within 3 months postoperatively. There was a significant difference in fusion scores between groups A, B, and C at 6 months postoperatively (F=3.904; P=.043) ( Table 3) .
Stepwise multiple comparisons showed a significant difference between groups A and B (P=.022), indicating that the fusion caused by autogenous iliac bone grafting was greater than that of the cervical interbody fusion cage containing ß-TCP. No significant difference was observed between groups A and C (P=.753), suggesting that the cervical interbody fusion cage containing ß-TCP and autogenous iliac bone grafting achieved similar intervertebral fusion. However, there was a significant difference between groups B and C (P=.04), demonstrating that the addition of BMP significantly increased fusion as compared with the cervical interbody fusion cage containing ß-TCP. The fusion scores in groups A, B, and C were not significantly different at 3 months postoperatively as compared with those at 6 months postoperatively (P=.156, .484, and .217, respectively). However, mean fusion scores in groups A, B, and C were higher at 6 months postoperatively compared with those at 3 months postoperatively. Intervertebral fusion was observed to be better at 6 months postoperatively than at 3 months postoperatively.
Analysis of Hard Tissue Sections
Three months postoperatively, most of the central loose parts of the cervical interbody fusion cage were degraded, and new bones formed normally. The central loose part was further degraded within 6 months postoperatively, and the new bones integrated with the dense part of the cervical interbody fusion cage (Figure 3) .
The NBA in group B was not significantly different at 3 months postoperatively compared with that at 6 months postoperatively (P=.884). However, the NBA in group C was significantly different at 3 months postoperatively compared with that at 6 months postoperatively (P=.014). This further indicated that the cervical interbody fusion cage containing ß-TCP+ErhBMP-2 significantly increased the NBA with time. There were significant differences between groups B and C at 3 and 6 months postoperatively (both P=0), suggesting that the cervical interbody fusion cage containing ß-TCP+ErhBMP-2 had a higher increase in the NBA compared with that of the cervical interbody fusion cage containing ß-TCP.
The RMA in groups B and C was not significantly different at 3 months postoperatively compared with that at 6 months postoperatively (P=.438 and .208, respectively). This observation further indicated that the cervical interbody fusion cage containing ß-TCP, with or without ErhBMP-2, resulted in no significant reduction in the RMA at 3 and 6 months postoperatively. There were significant differences in the RMA between groups B and C at 3 and 6 months postoperatively (P=.007 and .008, respectively). This further suggested that the cervical interbody fusion cage containing ß-TCP+ErhBMP-2 had a higher RMA reduction compared with that of the cervical interbody fusion cage containing ß-TCP at 3 and 6 months postoperatively.
The MDR in group B was not significantly different at 3 months postoperatively compared with that at 6 months postoperatively (P=.497), whereas in group C, it was significantly different (P=.016). This further showed that the cervical interbody fusion cage containing ß-TCP+ErhBMP-2 had a higher MDR at 6 months postoperatively compared with that at 3 months postoperatively. There were significant differences in the MDR between groups B and C at 3 and 6 months postoperatively (P=.005 and .001, respectively), suggesting that the cervical interbody fusion cage containing ß-TCP+ErhBMP-2 had a significantly higher MDR compared with that of the cervical interbody fusion cage containing ß-TCP at 3 and 6 months postoperatively.
The DTP in groups B and C was not significantly different at 3 months postoperatively compared with that at 6 months postoperatively (P=.872 and .187, respectively). This further confirmed that the cervical interbody fusion cage containing ß-TCP, with or without ErhBMP-2, resulted in no significant change in DTP with time. There were significant differences in DTP between groups B and C at 3 and 6 months postoperatively (P=.028 and .022, respectively). This finding suggested that the cervical interbody fusion cage containing ß-TCP+ErhBMP-2 had a higher DTP compared with that of the cervical interbody fusion cage containing ß-TCP at 3 and 6 months postoperatively. Similar results were observed in the mean ratio of penetration depth (DTP/4.5 mm).
The integration ratio of new bone and the dense part of the fusion cage in groups B and C was not significantly different at 3 months postoperatively compared with that at 6 months postoperatively (P=.888 and .261, respectively). This observation further indicated that the cervical interbody fusion cage containing ß-TCP, with or without ErhBMP-2, achieved similar integration in the dense part of the fusion cage and the bone tissues. There were significant differences in the integration ratio of new bone and the dense part of the fusion cage between groups B and C at 3 and 6 months postoperatively (P=.014 and .002, respectively). This finding suggested that the cervical interbody fusion cage containing ß-TCP+ErhBMP-2 achieved a better integration between the dense part of the fusion cage and the bone tissues compared with that of the cervical interbody fusion cage containing ß-TCP at 3 and 6 months postoperatively ( Table 4) .
discussion
Clinically used rhBMP-2 has been proven to effectively increase bone fusion after cervical and lumbar spine surgery. Furthermore, the fusion rate caused by rh-BMP-2 was not different from that caused by the autogenous iliac bone grafting. 14, 19 In addition, administration of rhBMP-2 eliminated the complications caused by the harvesting of autogenous iliac bone. However, the rhBMP-2 derived from eukaryocytes has many problems, including low production and high cost.
4 E coli-derived rhBMP-2 has the potential for largescale production; however, all proteins generated are present in insoluble inclusion bodies. Because the prokaryotic expression systems lack the process of posttranslational modification, including glycosylation, dimer formation, and removal of preproteins, ErhBMP-2 has no biological activity. 4 In addition, the procedures are time consuming and complex, especially at late stages such as renaturation and purification, which causes the gross production of ErhBMP-2 to remain low. 4 It has been reported that the activity of ErhBMP-2 was inferior to that of traditional rhBMP. 10 However, more positive effects of ErhBMP-2 have been recently observed. E coli-derived rhBMP-2 and CHO-derived rhBMP-2 (CHO-rhBMP-2) have been shown to have similar efficacy in the repair of skull defects in rat models. 6 Lee et al 20 found that CHO-rhBMP-2 and ErhBMP-2 had similar activity in the repair of canine mandibular bone defects. In addition, ErhBMP-2 and CHO-rhBMP-2 have been reported to show similar ability in the repair of canine long bone defects. 12 The current study's findings showed that the intervertebral fusion caused by the cervical interbody fusion cage containing ß-TCP+ErhBMP-2 was not significantly different from that caused by autogenous iliac bone grafting. Furthermore, it achieved higher efficacy in intervertebral fusion compared with that of the cervical interbody fusion cage containing ß-TCP. The bony fusion of the cervical interbody fusion cage containing ß-TCP at surgical segments was not significantly different from that of autogenous iliac bone grafting at 3 months postoperatively, as revealed by assessment of fusion scores. The bony fusion caused by the cervical interbody fusion cage containing ß-TCP+ErhBMP-2 was not inferior to that of autogenous iliac bone grafting at 6 months postoperatively, which was significantly superior to that of the cervical interbody fusion cage containing ß-TCP. The addition of ErhBMP-2 led to significant increases in NBA, mean depth of penetration into the fusion cage, and degradation of the fusion cage. In addition, the fusion gradually increased with time, and a higher integration was found between the dense part of the fusion cage and new bone. Therefore, the efficacy of ErhBMP-2 in the induction of bone formation was not inferior to that of autogenous iliac bone grafting. It was further assumed that the efficacy of ErhBMP-2 was similar to that of CHO-rhBMP-2 in the induction of bone formation. If these problems, including instability, low activity, and immune rejection, could be solved, the large-scale production of rhBMP could be conducted through its expression in prokaryotes. This would mean a less expensive preparation and clinical application for rhBMP. 4 The use of BMP is generally considered safe 14, 21 ; however, it has been reported that the application of BMP could lead to many complications, including heterotopic ossification, seroma, poor wound healing, soft tissue edema, tracheal injury, radiculopathy, fusion cage subsidence, and lamina terminalis erosion. 20 The bone resorption and degradation caused by the use of BMP might contribute to the indirect consequences of BMP-stimulated osteoclast differentiation and expression of the receptor activator of nuclear factorkappa-B ligand (RANKL) or the direct consequence of osteoclast formation. 22 Loss of postoperative intervertebral height should be noted in interbody fusions. Whether the use of ErhBMP-2 induces the fusion cage to subside remains unknown. However, there have been some occasions where the fusion cage was subsided following the use of CHOrhBMP-2. 23 Dohzono et al 22 and Lee et al 24 studied posterior lateral fusion of the lumbar spine in small animals, which did not subside the fusion cage. The current study's findings showed that autogenous iliac bone grafting caused a significantly greater loss of intervertebral space height compared with that caused by the cervical interbody fusion cage containing ß-TCP and the cervical interbody fusion cage containing ß-TCP+ErhBMP-2 6 months postoperatively. However, the loss of intervertebral space height caused by the cervical interbody fusion cage containing ß-TCP was not significantly different from that caused by the cervical interbody fusion cage containing ß-TCP+ErhBMP-2. Therefore, it is expected that the enhanced fusion cage containing ß-TCP will have a definite effect in maintaining interverte- E coli-derived rhBMP-2 has been shown to induce bone formation in a dosedependent manner. 22 Large-scale or excessive use of ErhBMP-2 might reduce bone formation and resorption. 22 Currently, the clinical dose of CHO-rhBMP-2 is large. 22 The maximum dose of ErhBMP-2 reported previously was 2.24 mg, which was used for the repair of canine long bone defects leading to bone resorption. 12 When ErhBMP-2 was used for rabbit spinal fusion at a maximum dose of 2 mg, bone resorption was also observed. 24 Therefore, there is no accurate information on the dose of ErhBMP-2 used for intervertebral fusion in large-animal models. Further studies are required to find a proper dose to avoid the occurrence of bone destruction and fusion cage subsidence caused by the use of ErhBMP-2. In this study, ErhBMP-2 was used at a dose of 2.5 mg, which was relatively high. However, no postoperative bone resorption was observed. Furthermore, the postoperative loss of intervertebral space height caused by administration of ErhBMP-2 was not significantly different from that caused by the use of the cervical interbody fusion cage containing ß-TCP. Therefore, there is no adequate evidence to prove that the administration of ErhBMP-2 at this dose might cause bone resorption or destruction.
This study has some limitations. The sample size was small and therefore inadequate. Each group contained only 6 goats. Therefore, nonparametric tests with low efficiencies were used to test the significance of differences between the groups. Some of the findings may not be reliable. For example, there were no significant differences in the fusion scores between 3 and 6 months postoperatively. Therefore, the results of this study may require further experimentation with a larger sample size to be validated. Furthermore, breakage of the fusion cage was observed in a few goats, which might be attributed to many factors: (1) the fusion cage did not fully match the shape of the upper and lower goat cervical vertebral plates, which led to discontinuous stress; (2) the fusion cage, made of TCP, lacked flexibility and had a high fragility; and (3) the cervical vertebrae of the goats were not immobilized.
Given the fact that no effective immobilization of the cervical vertebra was performed after the surgery, the cervical interbody fusion cage was easily broken under the stress caused by the goats' feeding or on violent neck movements. In addition, the goats' axial compression was significantly higher than that of humans. 25 The loss of intervertebral space height caused by the breakage of the fusion cage was confused as one of the ErhBMP-2 influencing factors, which could have led to some deviations in the observation and consequently the results. Finally, there was no comparison with CHO-rhBMP-2.
conclusion
The rhBMP-2 currently used in clinical practice and animal experiments is mainly derived from mammalian cell cultures, with a low production rate and high cost. However, ErhBMP-2 has an increased production but does not have any biological activities. This study demonstrated that ErhBMP-2 combined with an enhanced fusion cage containing ß-TCP had a high activity in the induction of bone formation in goat models. Furthermore, its ability to promote bone fusion was similar to that of autogenous iliac bone grafting. E coli-derived rh-BMP-2 promoted the degradation of absorbable fusion cages as well as the integration between the fusion cage and new bone. In addition, ErhBMP-2 had no obvious effects on maintaining the intervertebral space height and did not induce fusion cage subsidence. The biological activity of ErhBMP was similar to that of CHO-rhBMP-2 in intervertebral fusion, and it can be applied in clinical practice.
